

I registri come importante fonte di *real world data*: l'esperienza del Registro Italiano Sclerosi Multipla e Patologie Correlate

Registers as central real world data source: the experience of the Italian Multiple Sclerosis and Related Disorders Register

Michela Ponzio¹, Mario Alberto Battaglia¹, Maria Trojano², Marco Salivetto¹, Antonio D'Ettore³, Donatella Corrado³, Pasquale Paletta³, Vito Lepore³, Paola Mosconi,³ Comitato scientifico del Registro Italiano Sclerosi Multipla e Patologie Correlate,* Rete dei Centri del Registro Italiano Sclerosi Multipla e Patologie Correlate,* Rete degli assistenti di ricerca del Registro Italiano Sclerosi Multipla e Patologie Correlate*

¹ Area Ricerca Scientifica, Fondazione Italiana Sclerosi Multipla, Genova

² Centro Sclerosi Multipla, Dipartimento di Biomedicina Traslazionale e Neuroscienze (DiBrain), Università di Bari

³ Struttura Tecnico Operativa, Laboratorio di Ricerca per il Coinvolgimento dei Cittadini in Sanità, Dipartimento di Epidemiologia Medica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano

*Vedi box all'interno dell'articolo

Corrispondenza: Michela Ponzio; michela.ponzio@aism.it

Materiali supplementari

Studi basati sui dati del Registro Italiano Sclerosi Multipla

1. Trojano M, Bergamaschi R, Amato MP et al. The Italian multiple sclerosis register. *Neurol Sci* 2019;40(1):155-65. doi: 10.1007/s10072-018-3610-0. Erratum in: *Neurol Sci* 2019;40(4):907.
2. Paolicelli D, Lucisano G, Manni A et al. Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. *J Neurol* 2019;266(12):3098-107. doi: 10.1007/s00415-019-09531-6
3. Chisari CG, Grimaldi LM, Salemi G et al. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2020;91(12):1297-303. doi: 10.1136/jnnp-2020-323472
4. Patti F, Visconti A, Capacchione A, Roy S, Trojano M; CLARINET-MS Study Group. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). *Ther Adv Neurol Disord* 2020;13:1756286420922685. doi: 10.1177/1756286420922685
5. Amato MP, Fonderico M, Portaccio E et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. *Brain* 2020;143(10):3013-24. doi: 10.1093/brain/awaa251
6. Lepore V, Bosetti C, Santucci C et al. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. *Eur J Neurol* 2021;28(2):567-78. doi: 10.1111/ene
7. Iaffaldano P, Lucisano G, Butzkueven H et al. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. *Mult Scler* 2021;27(10):1543-55. doi: 10.1177/13524585211010128
8. Hillert J, Magyar M, Soelberg Sørensen P et al. Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. *Front Neurol* 2021;12:647811. doi: 10.3389/fneur.2021.647811
9. D'Amico E, Zanghì A, Romeo M et al. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. *Neurotherapeutics* 2021;18(2):905-19. doi:10.1007/s13311-020-01001-6
10. Zanghì A, Avolio C, Amato MP et al. First-line therapies in late-onset multiple sclerosis: An Italian registry study. *Eur J Neurol* 2021;28(12):4117-23. doi: 10.1111/ene.15006
11. Baroncini D, Simone M, Iaffaldano P et al. Risk of Persistent Disability in Patients with Pediatric-Onset Multiple Sclerosis. *JAMA Neurol* 2021;78(6):726-35. doi: 10.1001/jamaneurol.2021.1008
12. Ferraro D, Iaffaldano P, Guerra T et al. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. *J Neurol* 2022;269(3):1463-69. doi: 10.1007/s00415-021-10708-1
13. Iaffaldano P, Lucisano G, Caputo F et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. *Ther Adv Neurol Disord* 2021;14:17562864211019574. doi: 10.1177/17562864211019574
14. Iaffaldano P, Lucisano G, Patti F et al. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. *Mult Scler* 2021;27(3):430-38. doi: 10.1177/1352458520974366
15. Chisari CG, Comi G, Filippi M et al. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. *J Neurol* 2022;269(2):933-44. doi: 10.1007/s00415-021-10676-6

16. Zanghì A, Avolio C, Amato MP et al. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register. *Mult Scler Relat Disord* 2022;58:103489. doi: 10.1016/j.msard.2022.103489
17. De Meo E, Filippi M, Trojano M et al. Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis. *Ann Neurol* 2022;91(4):483-95. doi: 10.1002/ana.26322
18. Iaffaldano P, Lucisano G, Manni A et al. Risk of Getting COVID-19 in People with Multiple Sclerosis: A Case-Control Study. *Neurol Neuroimmunol Neuroinflamm* 2022;9(2):e1141. doi: 10.1212/NXI.0000000000001141
19. Portaccio E, Bellinvia A, Fonderico M et al. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. *Brain* 2022;145(8):2796-805. doi: 10.1093/brain/awac111
20. Portaccio E, Fonderico M, Iaffaldano P et al. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients with Primary Progressive Multiple Sclerosis. *JAMA Neurol* 2022;79(9):869-78. doi: 10.1001/jamaneurol.2022.1929
21. Bergamaschi R, Beghi E, Bosetti C et al. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. *Neurol Sci* 2022;43(9):5459-69. doi: 10.1007/s10072-022-06169-7
22. Iaffaldano P, Lucisano G, Guerra T et al. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. *Mult Scler* 2022;28(14):2243-52. doi: 10.1177/13524585221114007
23. Signori A, Lorscheider J, Vukusic S et al. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. *J Neurol Neurosurg Psychiatry* 2023;94(1):23-30. doi: 10.1136/jnnp-2022-329987
24. Boffa G, Signori A, Massacesi L et al. Hematopoietic Stem Cell Transplantation in People with Active Secondary Progressive Multiple Sclerosis. *Neurology* 2023;100(11):e1109-22. doi: 10.1212/WNL.0000000000206750
25. Mosconi P, Guerra T, Paletta P et al. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register. *Neurol Sci* 2023;44(11):4001-11. doi: 10.1007/s10072-023-06876-9
26. Zanghì A, Galgani S, Bellantonio P et al. Relapse-associated worsening in a real-life multiple sclerosis cohort: the role of age and pyramidal phenotype. *Eur J Neurol* 2023;30(9):2736-44. doi: 10.1111/ene.15910
27. Chisari CG, Bianco A, Brescia Morra V et al. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY). *Neurotherapeutics* 2023;20(6):1696-706. doi: 10.1007/s13311-023-01415-y
28. Iaffaldano P, Portaccio E, Lucisano G et al. Multiple Sclerosis Progression and Relapse Activity in Children. *JAMA Neurol* 2024;18(1):50-58. doi: 10.1001/jamaneurol.2023.4455
29. Bisecco A, Matrone F, Capobianco M et al. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients. *J Neurol* 2024;271(2):699-710. doi: 10.1007/s00415-023-12084-4
30. Iaffaldano P, Lucisano G, Guerra T et al. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry. *J Neurol* 2024;271(3):1150-59. doi: 10.1007/s00415-023-12137-8
31. Lorefice L, Ferraro OE, Fenu G et al. Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry. *J Neurol* 2024;271(4):1630-37. doi: 10.1007/s00415-023-12152-9
32. Sharmin S, Roos I, Malpas CB et al. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. *Lancet Child Adolesc Health* 2024;8(5):348-57. doi: 10.1016/S2352-4642(24)00047-6

33. Portaccio E, Betti M, De Meo E et al. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression. *J Neurol* 2024;271(8):5074-82. doi: 10.1007/s00415-024-12448-4
34. Chisari CG, Aguglia U, Amato MP et al. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study. *Neurotherapeutics* 2024;21(4):e00363. doi: 10.1016/j.neurot.2024.e00363
35. Lepore V, Paletta P, Bosetti C et al. Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register. *Mult Scler Relat Disord* 2024;87:105638. doi: 10.1016/j.msard.2024.105638
36. Iaffaldano P, Lucisano G, Guerra T et al. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis. *Ann Clin Transl Neurol* 2024;11(8):2008-2015. doi: 10.1002/acn3.52118